Evogene Ltd. recently announced an expanded phase of its collaboration with Google Cloud, focusing on integrating advanced AI Agents into its ChemPass AI platform. This proprietary engine for small-molecule discovery will leverage Google Cloud’s Vertex AI platform to enhance the speed, precision, and efficiency of drug and ag-chemical development.
This marks a significant milestone in the partnership, building on the successful collaboration initiated in October 2024, which established a generative AI foundation model as a core component of ChemPass AI. The introduction of AI agents is expected to broaden Evogene’s offerings and accelerate future partnerships, highlighting the company’s commitment to innovation in molecular design.
AI agents are designed to automate complex scientific workflows, enabling large-scale molecular exploration and improving the accuracy of small-molecule product design. This integration aligns with Evogene’s goal of identifying high-quality small molecules that meet stringent commercial criteria, reinforcing its leadership in next-generation molecular design for pharmaceutical and agricultural markets.
Boaz Maoz from Google Cloud emphasized the collaboration’s potential to enhance scientific research through AI integration, while Ofer Haviv, Evogene’s CEO, noted the expected improvements in speed and cost structure, as well as the potential for global accessibility of their innovation tools via Google Cloud Marketplace. This collaboration signifies a shift towards autonomous discovery, positioning ChemPass AI for a new phase of scalability and execution.
Evogene Ltd. (Nasdaq/TASE: EVGN) is a leader in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural sectors. Its ChemPass AI platform significantly enhances success rates and reduces development time and costs, driving breakthrough products through real-world innovation.
Get started today with Solo access →
